Abstract
BACKGROUND. Interleukin-6 (IL-6) is a multifunctional regulator of cellular events in prostate cancer. LNCaP-IL-6+ cells selected in the presence of IL-6 were taken for assessment of effects of the chimeric monoclonal anti-IL-6 antibody CNTO 328. METHODS. Cell viability was assessed after treatment with CNTO 328 by the ATP assay. Expression of Bcl-2 and Bax and activation of signaling pathways were evaluated by Western analysis. Nude mice were inoculated with LNCaP-IL-6+ cells and treated with CNTO 328. The tumors were analyzed by immunohistochemistry for expression of Ki-67, tissue transglutaminase, and vascular endothelial growth factor. RESULTS. CNTO 328 caused a statistically significant inhibition of cell viability. The protein levels of Bcl-2 and the phosphorylation of ERK1/2 mitogen-activated protein kinases were decreased by the anti-IL-6 antibody. Treatment with CNTO 328 yielded an increase in the phosphorylation of signal transducers and activators of transcription factor 3. The mean tumor volume in animals inoculated with LNCaP-IL-6+ cells and treated with CNTO 328 was insignificantly lower than that in animals treated with the control antibody. There was a statistically significant decrease in the percentage of Ki-67-positive cells in CNTO 328-treated tumors. CONCLUSION. CNTO 328 has a potential in prostate cancer therapy and could be further tested in various combination experimental treatments.
Original language | English |
---|---|
Pages (from-to) | 1744-1752 |
Number of pages | 9 |
Journal | Prostate |
Volume | 66 |
Issue number | 16 |
DOIs | |
Publication status | Published - Dec 1 2006 |
Keywords
- Interleukin-6
- Monoclonal antibody
- Prostate tumor
- Targeted therapy
- Xenografts
ASJC Scopus subject areas
- Urology